Labcorp’s October 2026 acquisition spree signals a broader push toward specialty diagnostics consolidation.
Within nine days, Labcorp announced three acquisitions across distinct segments of the diagnostics market:
• Myriad Genetics’ Prenatal Health Business ($210M): Expands reproductive genetics testing and adds an estimated 14% share of completed US NIPTs.
• BioReference Health ($722M upfront): Adds clinical laboratory operations in the Northeast and the FDA-approved 4Kscore prostate cancer test.
• Millennium Health (Undisclosed): Expands specialty toxicology, medication monitoring and drug surveillance capabilities.
The transactions highlight a shift toward national laboratory platforms acquiring specialized technologies and established testing volumes. Labcorp can use its physician relationships, payer contracts and laboratory network to expand the reach of these acquired products, potentially increasing competition for regional laboratories and independent specialty diagnostics providers. For Labcorp, the opportunity extends beyond acquired revenue. Recovering Myriad’s declining prenatal testing volumes, scaling 4Kscore nationally through primary care and integrating Millennium’s specialized testing into its existing network could drive market share gains and improve laboratory utilization.
Labcorp Accelerates Specialty Diagnostics Expansion
Labcorp Overview
Synergy with Myriad Genetics
Strategic Synergy with Labcorp
Expands Labcorp’s reproductive genetics portfolio with FirstGene, AMPLIFY technology and Foresight carrier screening.
Adds Myriad’s estimated 14% share of completed US NIPTs, strengthening Labcorp’s position against Natera and BillionToOne.
Leverages Labcorp’s OB/GYN network and payer relationships to recover declining testing volumes and increase adoption.
Synergy with Bioreference
Strategic Synergy with Labcorp
Adds the FDA-approved 4Kscore Test, opening opportunities to expand prostate cancer testing into primary care.
Adds 80+ patient service centers across New York and New Jersey, increasing regional market share.
Consolidates testing volumes into existing laboratories to reduce costs and improve utilization.
Uses Labcorp’s national network to expand 4Kscore adoption beyond BioReference’s existing customers.
Synergy with Millennium Health
Strategic Synergy with Labcorp
Expands Labcorp’s specialty toxicology portfolio with definitive urine and oral fluid drug testing.
Integrates Millennium’s Emerging Threat Intelligence platform for drug surveillance and trend analysis.
Adds chronic pain, behavioral health and substance use treatment providers to Labcorp’s clinical network.
Creates opportunities for cross-selling, higher testing volumes and improved billing compliance.
See the Full Report Below: